Physiomics PLC has developed Virtual Tumour Clinical, an in silico model of human tumour cell populations that can be used to optimise drug treatment regimens for the clinic. Accurately predicting the human scenario would have a major impact on attrition rate, while reducing animal use in anticancer drug discovery. Partners are sought to help calibrate the new in silico model for optimising drug treatment regimens in clinical cancer studies. For further information please see the flyer.